Expression of HIF-1α and its relationship with prognosis in papillary renal cell carcinoma

doi:10.16150/j.1671-2870.2021.03.007

Abstract

Abstract:

Objects: To investigate the expression of hypoxia inducible factor-1ɑ（HIF-1ɑ） in papillary renal cell carcinoma (PRCC) and its relationship with microvessel density so as to explore the correlation of HIF-1ɑ expression with prognosis in PRCC patients. Methods: Immunohistochemistry was used to detect the expression of HIF-1ɑ in PRCC and para-carcinoma tissue and the relationship between expression of HIF-1ɑ and MVD was analyzed. Survival data were eva-luated with Kaplan-Meier and Log-rank method, and the significant factors were further analyzed with Cox model multivariate regression analysis. Results: The positive expression rate of HIF-1ɑ was 42.17% (35/83), and the positive expression rates in typeⅠand type II PRCC were 32.65% and 55.88%, respectively. The MVD in typeⅡPRCC was higher than that in typeⅠPRCC (40.74 /HP vs 25.63/HP), and HIF-1ɑ expression was positively correlated with MVD (γ=0.65). The 5-year survival rate of 83 PRCC patients was 89.16% (74/83), and of the 13 death cases, 10 cases were type Ⅱ PRCC. The Kaplan-Meier survival curve analysis showed that typeⅠPRCC had a better prognosis than typeⅡ. Univariate analysis revealed that Fuhrman grade Ⅲ-Ⅳ, occurrence of distant metastasis and HIF-1ɑ expression were risk factors for prognosis in PRCC patients (P<0.05). Multivariate analysis showed that HIF-1ɑ expression, Fuhrman grade, subtype of PRCC and distant metastasis were risk factors for poor prognosis. Conclusions: HIF-1ɑ expression is higher in typeⅡPRCC than in typeⅠPRCC, and HIF-1ɑ expression is a risk factor for poor prognosis in PRCC patients.

Key words: Papillary renal cell carcinoma, Hypoxia inducible factor-1α, Microvessel density, Prognosis

CLC Number:

R737.1

RUI Wenbin, XU Da, ZHU Yu, WU Yuxuan, WANG Haofei, WANG Chenghe, YUAN Fei. Expression of HIF-1α and its relationship with prognosis in papillary renal cell carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(03): 265-370.

Figures/Tables 8

References 26

[1]	Faria M, Shepherd P, Pan Y, et al. The estrogen receptor variants β₂ and β₅ induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling[J]. Oncotarget, 2018, 9(91):36273-36288. doi: 10.18632/oncotarget.26345 URL
[2]	Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene[J]. Cancer Cell, 2003, 3(4):347-361. pmid: 12726861
[3]	Zhang K, Xu P, Sowers JL, et al. Proteome analysis of hypoxic glioblastoma cells reveals sequential metabolic adaptation of one-carbon metabolic pathways[J]. Mol Cell Proteomics, 2017, 16(11):1906-1921. doi: 10.1074/mcp.RA117.000154 URL
[4]	Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and cancer[J]. J Clin Invest, 2016, 126(10):3689-3698. doi: 10.1172/JCI84430 URL
[5]	Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases[J]. Cancer Res, 1999, 59(22):5830-5835. pmid: 10582706
[6]	Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147(1):9-19. pmid: 7541613
[7]	Gudas LJ, Fu L, Minton DR, et al. The role of HIF1α in renal cell carcinoma tumorigenesis[J]. J Mol Med (Berl), 2014, 92(8):825-836. doi: 10.1007/s00109-014-1180-z URL
[8]	Chintala S, Najrana T, Toth K, et al. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of hypoxia-inducible factor 1 and 2 alpha by sele-nium in clear cell renal cell carcinoma leads to tumor growth inhibition[J]. BMC Cancer, 2012, 12:293. doi: 10.1186/1471-2407-12-293 URL
[9]	Medina Villaamil V, Aparicio Gallego G, Santamarina Caínzos I, et al. Searching for Hif1-α interacting proteins in renal cell carcinoma[J]. Clin Transl Oncol, 2012, 14(9):698-708. doi: 10.1007/s12094-012-0857-4 pmid: 22926943
[10]	Lidgren A, Hedberg Y, Grankvist K, et al. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray[J]. Eur Urol, 2006, 50(6):1272-1277. pmid: 16814458
[11]	Saleeb RM, Plant P, Tawedrous E, et al. Integrated phenotypic/genotypic analysis of papillary renal cell carcinoma subtypes: identification of prognostic markers, cancer-related pathways, and implications for therapy[J]. Eur Urol Focus, 2018, 4(5):740-748. doi: S2405-4569(16)30139-0 pmid: 28753789
[12]	Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma[J]. Cancer Cell, 2011, 20(4):511-523. doi: 10.1016/j.ccr.2011.08.024 URL
[13]	董樑, 黄吉炜, 奚倩雯, 等. 乳头状肾细胞癌的临床病理特征和预后分析[J]. 中华泌尿外科杂志, 2015, 36(3):183-187.
[14]	高明珠, 王进有, 张海梁, 等. 乳头状肾癌的临床病理特征及其预后因素[J]. 中国癌症杂志, 2014, 24(4):299-303.
[15]	Chen Y, Shuch B, Kluger H, et al. High WHO/ISUP Grade and unfavorable architecture, rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis[J]. Am J Surg Pathol, 2020, 44(5):582-593. doi: 10.1097/PAS.0000000000001455 pmid: 32101890
[16]	Ren W, Gao X, Zhang X, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management[J]. Clin Transl Oncol, 2020, 22(5):725-733. doi: 10.1007/s12094-019-02181-0 pmid: 31317521
[17]	Feng J, Xie G, Zhan Y, et al. Elevated HSP90 associates with expression of HIF-1α and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma[J]. Histopathology, 2019, 75(2):202-212. doi: 10.1111/his.13862 URL
[18]	Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colo-rectal cancers[J]. Am J Pathol, 2010, 176(5):2292-2301. doi: 10.2353/ajpath.2010.090972 URL
[19]	Swartz JE, Pothen AJ, van Kempen PM, et al. Poor prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinomas that overexpress hypoxia inducible factor-1α[J]. Head Neck, 2016, 38(9):1338-1346. doi: 10.1002/hed.24445 URL
[20]	Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 159:103231. doi: 10.1016/j.critrevonc.2021.103231 URL
[21]	Minardi D, Lucarini G, Santoni M, et al. Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1alpha expression[J]. Anticancer Res, 2015, 35(1):433-438.
[22]	Ebru T, Fulya OP, Hakan A, et al. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma[J]. Int Braz J Urol, 2017, 43(3):440-454. doi: 10.1590/s1677-5538.ibju.2015.0521 URL
[23]	Fan Y, Li H, Ma X, et al. Prognostic significance of hypoxia-inducible factor expression in renal cell carcinoma: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine(Baltimore), 2015, 94(38):e1646.
[24]	Deng J, Li L, Xia H, et al. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis[J]. Medicine (Baltimore), 2019, 98(27):e16309. doi: 10.1097/MD.0000000000016309 URL
[25]	Stenman M, Staehler M, Szabados B, et al. Metastatic papillary renal cell carcinoma in the era of targeted the-rapy - a retrospective study from three European academic centres[J]. Acta Oncol, 2019, 58(3):306-312. doi: 10.1080/0284186X.2018.1537505 pmid: 30507262
[26]	Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase Ⅱ study (SUPAP) by the French Genitourinary Group (GETUG)[J]. Ann Oncol, 2015, 26(6):1123-1128. doi: S0923-7534(19)31819-8 pmid: 32018840

临床特征	例数(n)	HIF-1α		MVD（个/高倍镜）
临床特征	例数(n)	阴性	阳性	MVD（个/高倍镜）
性别
男	58	31	27	32.60±12.45
女	25	17	8	30.60±10.77
年龄（岁）
≤55	44	20	24	33.50±13.36
>55	39	28	11	30.31±10.02
体重（kg）
≤60	23	12	11	36.87±13.72
>60	60	36	24	30.13±10.74
PRCC分型
Ⅰ型	49	33	16	28.61±9.39
Ⅱ型	34	15	19	36.88±13.59
Fuhrman核分级
Ⅰ、Ⅱ	50	32	18	30.14±10.23
Ⅲ、Ⅳ	33	16	17	34.82±13.84
T分期
T₁、T₂	52	35	17	29.17±9.44
T₃、T₄	31	13	18	36.74±14.18
淋巴转移
无	78	46	32	31.99±11.80
有	5	2	3	32.20±15.66
远处转移
无	80	47	33	31.80±11.91
有	3	1	2	37.33±14.50

组别	例数(n)	HIF-1α			χ²值	P值
组别	例数(n)	阳性	阴性	阳性率(%)	χ²值	P值
Ⅰ型PRCC	49	16	33	32.65
Ⅱ型PRCC	34	19	15	55.88	4.44	0.035

组别	例数(n)	MVD（个/高倍镜）	Z值	P值
Ⅰ型PRCC	49	28.61±9.39	0.007^a)	-2.70^a)
Ⅱ型PRCC	34	36.88±13.59	0.001^a)	-3.30^a)
正常肾组织	15	14.07±5.95

组别	例数(n)	MVD（个/高倍镜）	r值	P值
HIF-1α阳性组	35	25.63±5.44
HIF-1α阴性组	48	40.74±12.92	0.63	<0.001

变量	单因素分析		Cox回归
变量	r	P值	r	P值
性别	-0.22	0.98	0.04	0.910
年龄	0.01	0.99	0.01	0.450
体重	-0.22	0.55	0.11	0.500
亚型	11.74	0.06	-0.78	<0.001
Fuhrman分级（Ⅰ+Ⅱ比Ⅲ+Ⅳ）	-23.57	<0.01	0.76	0.020
T分期(T_1~2比T_3~4)	-7.14	0.28	0.16	0.590
N分期(N₀比N₁)	-16.53	0.19	-0.41	0.600
M分期(M₀比M₁)	-36.60	0.03	1.00	<0.001
HIF-1α	-29.38	<0.01	1.18	0.001